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Graves’ hyperthyroidism is caused by autoantibodies directed against the thyroid-
stimulating hormone receptor (TSHR) that mimic the action of TSH. The establishment 
of Graves’ hyperthyroidism in experimental animals has proven to be an important 
approach to dissect the mechanisms of self-tolerance breakdown that lead to the 
production of thyroid-stimulating TSHR autoantibodies (TSAbs). “Shimojo’s model” was 
the first successful Graves’ animal model, wherein immunization with fibroblasts cells 
expressing TSHR and a major histocompatibility complex (MHC) class II molecule, but 
not either alone, induced TSAb production in AKR/N (H-2k) mice. This model highlights 
the importance of coincident MHC class II expression on TSHR-expressing cells in the 
development of Graves’ hyperthyroidism. These data are also in agreement with the 
observation that Graves’ thyrocytes often aberrantly express MHC class II antigens 
via mechanisms that remain unclear. Our group demonstrated that cytosolic self-
genomic DNA fragments derived from sterile injured cells can induce aberrant MHC 
class II expression and production of multiple inflammatory cytokines and chemokines 
in thyrocytes in vitro, suggesting that severe cell injury may initiate immune responses 
in a way that is relevant to thyroid autoimmunity mediated by cytosolic DNA signaling. 
Furthermore, more recent successful Graves’ animal models were primarily established 
by immunizing mice with TSHR-expressing plasmids or adenovirus. In these models, 
double-stranded DNA vaccine contents presumably exert similar immune-activating 
effect in cells at inoculation sites and thus might pave the way toward successful Graves’ 
animal models. This review focuses on evidence suggesting that cell injury-derived self-
DNA fragments could act as Graves’ disease triggers.
Keywords: Graves’ disease, thyroid-stimulating hormone receptor, major histocompatibility complex class ii, 
genomic DNA, experimental animal models
iNTRODUCTiON
Graves’ disease is a unique human autoimmune disease that involves stimulating autoantibod-
ies directed toward thyroid-stimulating hormone receptors (TSHRs) on the surface of thyroid 
epithelial cells. This disease occurs in approximately 3% of females and 0.5% of males in the 
general population (1). Unlike autoantibodies to thyroglobulin (Tg) or thyroid peroxidase (TPO), 
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thyroid-stimulating TSHR autoantibodies are not just a marker 
of Graves’ disease but are also held directly responsible for the 
hyperthyroidism that occurs in most of the patients. Moreover, 
evidence suggests that only TSHR is the primary autoantigen 
of Graves’ disease, whereas immune responses to other thy-
roid antigens (e.g., Tg and TPO) simply reflect concomitant 
thyroiditis.
TSHR autoantibody was first discovered in a search for 
thyroid-stimulating activity in the serum of Graves’ disease 
patients, which was known to stimulate radioiodine release from 
pre-labeled guinea pig thyroids for a much longer time period 
than did pituitary TSH treatment (2). This prolonged stimulat-
ing activity present in the IgG fraction of Graves’ patient serum 
could compete with TSH for TSHR occupancy, which implies 
the presence of TSHR antibodies that act as TSHR agonists (3). 
Thus, in most Graves’ disease patients, circulating antibodies that 
have TSH-like activity continuously stimulate the thyroid. This 
continuous stimulation results in an enlarged thyroid known 
as goiter, and these patients have increased iodine uptake and 
overproduction of thyroid hormone (TH). Typical blood tests for 
Graves’ disease patients show elevated T3 and T4 levels, as well as 
low TSH (as a result of negative feedback loop) levels (4).
TSHR antibodies (TRAbs) in serum from Graves’ disease 
patients can now be clinically evaluated by non-radioactive third 
generation assay, in which the autoantibodies inhibit binding of a 
biotin-labeled human monoclonal thyroid-stimulating antibody 
M22 to TSHR-coated ELISA plate wells (5). However, TRAbs 
may or may not initiate a TSH-like intracellular signal. TRAbs 
that induce a strong TSH-like stimulatory signal are referred 
to as TSHR-stimulating antibodies/immunoglobulin (TSAbs/
TSI), which is the immunological hallmark of Graves’ disease. 
Meanwhile, TRAbs that induce weak or no stimulatory signals 
are referred to as TSHR-blocking antibodies (TBAbs). The TSAb 
activity of TRAbs is usually evaluated by their capacity to induce 
cAMP production in TSHR-expressing cells (6). TSAbs and 
TBAbs can sometimes coexist in the serum of an individual 
patient and may change over time. The clinical status of a patient 
who has both TSAbs and TBAbs presumably depends on the rela-
tive concentration and affinity of the predominant antibody type. 
A shift from TSAbs to TBAbs may occur during spontaneous or 
treatment-induced remission of Graves’ disease that may lead to 
the subsequent development of hypothyroidism (7). In addition 
to TRAbs, TPO and/or Tg antibodies are detectable in 25–75% of 
Graves’ disease patients, which is consistent with the lymphocytic 
infiltration seen in Graves’ thyroids and is typically less extensive 
than that seen for Hashimoto’s disease.
Although its characteristic hyperthyroidism symptoms and the 
availability of sensitive laboratory tests may make the diagnosis 
of Graves’ disease straightforward, the lack of an understanding 
of the pathogenic mechanisms of this disease has impeded the 
development of cures. In Graves’ disease, immune tolerance 
toward self-antigen TSHR is obviously dysfunctional, such that, 
from a classical point of view, endogenous TSHR processed in the 
cytosol of thyrocytes gives rise to peptides for human leukocyte 
antigen (HLA) class I presentation to CD8+ T cells. Alternatively, 
TSHR may be engulfed by antigen-presenting cells (APCs, typi-
cally macrophages, dendritic cells, and B cells) where it is digested 
in the lysosomes and destined for HLA class II presentation to 
CD4+ T cells. In order to dissect Graves’ disease pathogenesis, 
tremendous efforts have been made to develop experimental 
Graves’ animal models that have indeed provided invaluable 
insights for understanding the reasons behind the breakdown of 
self-tolerance.
ANiMAL MODeLS OF GRAveS’ DiSeASe
Autoimmune thyroiditis occurs spontaneously in several animal 
species (8–10); however, Graves’ disease develops spontaneously 
only in the humans. Conventional animal models of autoim-
mune thyroiditis that is produced by immunizing animals with 
Tg or TPO protein have long been available (11). After human 
TSHR was cloned, similar attempts were made to induce Graves’ 
disease by immunizing animals with human TSHR that was 
expressed either in a baculovirus expression system or in insect 
cells (12–16), or purified from cloned human thyroid cells (GEJ) 
(17). The TSHR is a member of the G protein-coupled receptor 
superfamily and is coupled with the Gs protein that activates 
the cAMP-dependent pathway (18). TSHR consists of a short 
cytoplasmic C-terminal tail, seven transmembrane regions, and 
a large extracellular horseshoe-shaped leucine-rich repeat region 
(LRR) known as the ectodomain (Figure 1) (18). TSHR report-
edly undergoes intramolecular cleavage at some portion of the 
single-chain polypeptide on the cell surface to form two subunits, 
such as A and B, which are linked by a hinge of disulfide bonds 
(19). The extracellular ectodomain (A subunit) of the cleaved 
receptor is also susceptible to loss by shedding (20, 21) (Figure 1). 
In addition, epitopes for TSAb, but not TBAb, are partially 
obstructed in wild-type TSHR by the plasma membrane, LRR, or 
TSHR dimerization. However, the TSAb epitope on the soluble A 
subunit that is shed from surface TSHR is freely accessible (22). 
These observations suggest that the shed A subunit, rather than 
the cell surface full-length TSHR, may be responsible for initiating 
or amplifying the autoimmune response to the TSHR that in turn 
leads to Graves’ hyperthyroidism. To provide evidence to support 
this concept, various TSHR ectodomain preparations instead of 
the full-length TSHR were more frequently used to immunize 
animals for the development of Graves’ disease animal models 
(12–16). Although serum antibodies and murine monoclonal 
antibodies against hTSHR were generated in these immunized 
animals, antibodies with TSAb activity were absent, despite the 
use of various TSHR preparations with different adjuvants in a 
variety of mouse strains. The animals did not display increased 
serum TH, goiter, or thyrocytes hypertrophy either. Human 
TSHR was thought not to be an authentic autoantigen and thus 
was unsuitable for inducing autoantibodies in mice. However, 
even immunization of mice with purified murine TSHR ectodo-
main expressed in insect cells with an adjuvant failed to induce 
hyperthyroidism (23).
Purified TSHR peptides expressed in bacteria or insect 
cells might lack a functional conformation that is needed to 
induce TSAb in animal models by conventional immuniza-
tion approaches. To overcome this obstacle, later models used 
immunization approaches that involved in vivo expression of 
THSR. In these models, animals are injected with transfected 
FiGURe 1 | Schematic representations of the TSHR protein, intramolecular cleavage, and A subunit shedding. TSHR consists of an A subunit that has a 
large extracellular horseshoe-shaped leucine-rich repeat region (LRR) known as the ectodomain, and a B subunit with seven transmembrane regions (left). TSHR 
undergoes intramolecular cleavage at a hinge-like single-chain polypeptide on the cell surface that connects the A and B subunits (middle). The cleaved receptor is 
susceptible to loss of the A subunit by shedding (right).
3
Luo et al. Cytosolic DNA Triggers Graves’ Disease
Frontiers in Endocrinology | www.frontiersin.org November 2016 | Volume 7 | Article 144
cells stably expressing hTSHR, or with plasmids or adenovirus 
for transient hTSHR expression. The first authentic animal 
model of Graves’ disease known as “Shimojo’s model” was 
generated by intraperitoneal immunization of female AKR/N 
(H-2k) mice with murine fibroblasts that stably expressed full-
length hTSHR and a major histocompatibility complex (MHC) 
class II molecule (24). The use of fibroblasts that express both 
TSHR and also MHC class II molecules was based on the 
observation of aberrant expression of MHC class II molecules 
on thyrocytes from patients with autoimmune thyroid diseases 
(AITD), including Graves’ disease (25). Such observations 
raised the possibility that TSHR might be presented to immune 
system by MHC class II-expressing thyrocytes that would break 
down normal immune tolerance (26). AKR/N (H-2k) mice 
were used for these models, as they have a homologous MHC 
class II I-A molecule that matches the expressed MHC class II 
molecule on fibroblasts (24). Approximately 20% of immunized 
mice produced TSAbs and showed increased T4 and T3 levels, 
as well as goiter with minimal lymphocyte infiltration (24). 
Intriguingly, immunizing mice with fibroblasts transfected 
with either TSHR or MHC class II alone did not induce Graves’ 
hyperthyroidism (24), indicating that aberrant expression of 
MHC class II molecules on cells expressing a native form of 
the TSHR can induce TSAb production. Shimojo’s group later 
tried the same approach with several different mouse strains 
that shared the H-2k haplotype but had different genetic 
backgrounds and found that, unlike AKR/N mice, C3H/He 
mice generated TBAbs even in the absence of MHC class II 
expression (27). However, simultaneous MHC class II expres-
sion was needed for TSAb production and development of 
hyperthyroidism (27). These results suggest that some genetic 
backgrounds are more susceptible to the induction of TRAbs, 
while for the development of functional TRAbs, aberrant MHC 
class II expression is necessary. Since “Shimojo’s model” was 
first described, many other independent groups have tried to 
reproduce and improve this model (28–31). For example, intra-
peritoneal immunization with TSHR-expressing M12 (B cells) 
induced Graves’ hyperthyroidism with TSAbs in 100% of 
immunized BALB/c mice (29, 30). Additionally, intraperitoneal 
immunization with hTSHR-expressing Chinese hamster ovary 
(CHO) cells induced Graves’ hyperthyroidism in 20% of immu-
nized female Chinese hamsters (28). A noteworthy detail of this 
study is that the CHO cells used in this immunization approach 
constitutively expressed MHC class II mRNA as demonstrated 
by RT-PCR (28). In addition to in  vivo expression of TSHR, 
the approaches in these studies shared immunization protocols 
that included cells that were either stably transfected with 
MHC class II-encoding cDNA (24, 27, 31, 32) or constitutively 
expressed MHC class II (28–30). This common feature also 
leads to a limitation wherein these models are only applicable to 
syngeneic animals that share the same MHC class II haplotype 
as the cells used for immunization. Thus, both the success and 
limitation seem to indicate an important role for aberrant MHC 
class II expression in the induction of TSAbs and development 
of Graves’ hyperthyroidism.
In order to overcome the strain limitation in Shimojo’s 
approach, novel immunization approaches that relied on 
intramuscular injection of plasmid vectors encoding TSHR to 
induce transient TSHR expression by myoblasts at the injection 
site (33), a method known as “naked” DNA vaccination, were 
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developed. Intramuscular TSHR DNA vaccination was first tried 
in female BALB/c mice, which gave rise to TRAbs with TBAb 
activity in 10 of the 14 immunized mice, whereas weak TSAb 
activity was detectable in only 1 mouse (34). Severe intrathyroi-
dal lymphocyte infiltration was observed in all the immunized 
mice, although none developed Graves’ hyperthyroidism (34). 
Thus, these initial attempts using DNA vaccination, despite their 
ability to generate TRAbs that recognized native TSHR, poorly 
fulfilled their initial promise of producing TSAbs. The TSHR 
DNA vaccination approaches were then modified, and different 
mouse strains were used. In outbred NMRI mice, intramuscular 
DNA vaccination produced TSAb and hyperthyroidism in 15% 
of females and 3% of males (35). For BALB/c mice, extensive 
lymphocyte infiltration was observed in most of the immunized 
outbred NMRI mice (35). Moreover, intradermal injection 
of TSHR DNA induced TSAb and hyperthyroidism in inbred 
female BALB/c mice at an incidence of 27% (36). Indeed, skin 
could be a better anatomical site for DNA vaccination since 
the skin is enriched in dendritic cells (Langerhans’ cells) that 
phagocytize and present antigens (36).
Thyroid-stimulating hormone receptor endogenously 
expressed by vaccination is presumably presented preferentially 
through the MHC class I antigen pathway; however, the involve-
ment of MHC class II presentation may also be necessary for 
optimal T cell signaling during TSAb production, as implied 
in “Shimojo’s model.” To test this hypothesis, Pichurin et  al. 
constructed a chimeric plasmid that encodes TSHR and the 
lysosome-associated membrane protein (LAMP)-1, which has a 
sorting signal that can direct TSHR into lysosomes and, conse-
quently, into the MHC class II presentation pathway. A chimeric 
TSHR–LAMP-1 plasmid was tested for its efficacy in intramus-
cular DNA vaccination. Remarkably, TSAb and hyperthyroidism 
were induced in approximately 20% of female BALA/c mice 
presumably through hijacking of the TSHR to the MHC class 
II presentation pathway (37). In contrast, no mice of the same 
strain injected with wild-type TSHR DNA vaccine showed TSAbs 
and hyperthyroidism (32). These results indicate that engaging 
MHC class II presentation facilitates the generation of TSAbs. 
Additionally, 30% of murine MHC class II knockout HLA-DR3 
transgenic NOD mice vaccinated with TSHR DNA showed TSAb 
induction and Graves’ hyperthyroidism (38). These observations, 
together with the results for BALB/c and outbred mice, indicate 
that, although theoretically DNA vaccination can be performed 
in any mouse strain, genetic background remains a decisive factor 
in DNA vaccination outcomes. Despite the various mouse strains 
tested and modifications to the immunization protocols, disease 
incidence induced by DNA vaccination was low (0–30%) (32, 
35–42). This low success rate can presumably be attributed to the 
relatively low TSHR expression efficiency afforded by plasmid 
vectors.
Substituting adenovirus for plasmid as the vector that encodes 
THSR cDNA has generally increased the incidence of Graves’ 
hyperthyroidism in mice. In the original report, intramuscular 
adenovirus (ad)-TSHR immunization induced TSAb and 
hyperthyroidism symptoms in 55 and 33% of female and male 
BALB/c mice, respectively. C57BL/6 mice were less susceptible 
in that only 25% of the females developed hyperthyroidism 
after the ad-TSHR immunization. Meanwhile, CBA/J, DBA/1J, 
and SJL/J mice were completely resistant to ad-TSHR-induced 
hyperthyroidism (43). By adapting the adenovirus vector to 
express the TSHR A subunit instead of full-length TSHR, the 
incidence of induced Graves’ disease was increased to approxi-
mately 65–80% in female BALB/c mice (44, 45). Although 
intramuscular injection of plasmid-TSHR was less effective 
than ad-TSHR for inducing Graves’ disease in mice, the adop-
tion of intramuscular electroporation for plasmid-TSHR genetic 
immunization has recently achieved considerable improvement 
in disease induction as manifested by in  vivo hTSHR expres-
sion and significantly increased disease incidence (46, 47). 
Surprisingly, TSAbs persisted for more than 8 months after the 
final electroporation immunization (46), which is in contrast to 
the transient hyperthyroidism induced by intramuscular immu-
nization wherein TSAb activity often began to decline much 
earlier or even completely disappeared (48). Another recently 
reported model of long-term Graves’ disease was established by 
prolonged intramuscular immunization with the ad-TSHR A 
subunit in female BALB/c mice (49). Long-term Graves’ models 
would be particularly useful for pharmacological analysis and 
for monitoring treatment response.
ABeRRANT eXPReSSiON OF MHC 
CLASS ii ON THYROCYTeS
By immunizing mice with fibroblasts transfected with both 
hTSHR and a MHC class II molecule, but not by either alone, 
Shimojo et al. was the first to successfully generate an authentic 
Graves’ mouse model (24). This model supported a previously 
proposed hypothesis that epithelial cells from organs that are 
highly susceptible to organ-specific autoimmunity can be induced 
to express MHC class II antigens and in turn present antigens to 
T cells (26). Unlike MHC class I, which is expressed in many types 
of nucleated cells, MHC class II expression is restricted to profes-
sional APCs, such as macrophages, dendritic cells, and B cells. 
However, aberrant MHC class II expression on thyroid epithelial 
cells is frequently seen in thyroid autoimmune diseases. Hanafusa 
et al. used immunofluorescence staining to demonstrate aberrant 
HLA-DR expression in discrete groups of follicles in 20 of the 
26 thyroids from patients with Graves’ disease, whereas none of 
11 specimens from normal thyroids did (25). Similarly, Jansson 
et al. reported that HLA-DR-positive thyrocytes were observed in 
9 of the 11 specimens of Graves’ thyroids by immunohistochemi-
cal staining (50). In addition to thyroid autoimmune diseases, 
aberrant HLA-DR expression on epithelial cells has also been 
noted in other organ-specific autoimmune diseases, including 
type I diabetic insulitis (51). Although MHC class II expression 
is not constitutive, immune mediators can induce MCH class 
II production in epithelial cells. Interferon (INF)-γ, known as 
the most prominent MHC class II stimulator, can induce MHC 
class II on thyrocytes both in  vitro and in  vivo (52–54). INF-γ 
is predominantly produced by lymphocytes as part of innate 
immune responses (55). Thus, whether aberrant MHC class 
II expression on Graves’ thyrocytes is secondary to coincident 
lymphocyte infiltration has been wondered. However, so far, 
the spatial relationship between HLA-DR-positive thyrocytes 
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and lymphocyte foci in Graves’ thyroids remains obscure due to 
conflicting observations (25, 50).
Besides the undetermined trigger for aberrant MHC class II 
expression on thyrocytes, little is known about MHC class II 
antigen presentation in these cells. In contrast to professional 
APCs, thyrocytes do not have naturally well-adapted machinery 
for either phagocytosis or antigen processing and presentation, 
and they do not migrate to lymphoid organs. Nevertheless, 
there are several lines of evidence to suggest that MHC class 
II-positive thyrocytes may present peptides to and directly 
interact with homologous T cells. Induced HLA-DR-positive 
thyrocytes could promote proliferation of autologous T cells 
in vitro, a phenomenon that does not occur in the absence of 
HLA-DR expression and is inhibited by HLA-DR monoclonal 
antibodies (56). Moreover, in a study of 18 Graves’ disease 
patients, expression of HLA-DR antigens on thyrocytes after 
primary culture in the absence of INFγ was seen in 12 patients, 
and this expression induced proliferation of autologous 
T  cells derived from both thyroids and peripheral blood (53, 
57). T lymphoblast generation was also observed after cultur-
ing normal spleen lymphocytes on monolayers of syngeneic 
thyrocytes for 3 days. Intriguingly, only these T lymphoblasts 
that had been sensitized on thyrocytes were specifically labeled 
with fluorescein-conjugated Tg (58). Additionally, primary 
Graves’ thyrocytes were shown to possess phagocytic activity 
that was enhanced by interleukin-2 and INF-γ and inhibited 
by antithyroid drugs and steroid medications (59). HLA-DR-
positive thyrocytes could present to cloned human T cells an 
influenza-specific peptide, but not an intact flu virus, and this 
reaction was blocked by HLA-DR antibodies (60).
Another intriguing question is how aberrantly expressed 
MHC class II on thyrocytes contributes to breaking self-toler-
ance. Pichurin et al. demonstrated that hijacking endogenously 
expressed TSHR into the MHC class II presentation pathway 
by using a chimeric plasmid encoding both TSHR and the 
lysosome-directing molecule LAMP was significantly more 
effective for inducing Graves’ hyperthyroidism in BALB/c mice 
than the use of plasmids encoding wild-type TSHR (37). This 
finding indicates that the more endogenous antigens entered the 
MHC class II pathway, the more TSAbs would be generated. 
Traditionally, immunologists held that MHC class I and II were 
restricted to the cytosol and endosomes/lysosomes, respec-
tively, for surveying distinct subcellular domains for ligands. 
However, alternative pathways for delivering exogenous anti-
gens to MHC class I have been characterized and are known as 
cross-presentation (61). On the other hand, the observation that 
a large proportion of peptides purified from MHC class II are 
derived from cytosolic self-proteins (e.g., metabolic enzymes, 
cytoskeletal proteins, and tumor antigens) indicates that MHC 
class II may also present endogenous peptides for CD4+ T cell 
recognition, which has potential relevance to autoimmunity 
and tumor immunity (62, 63). Endogenously expressed viral 
proteins were shown to be lysed by MHC class II-restricted 
virus-specific CD4+ T cells (64), indicating that endogenously 
expressed proteins can be presented by the MHC class II 
pathway for CD4+ T cell recognition. Moreover, endogenous 
antigen presentation by MHC class II could occur through both 
autophagy-dependent [reviewed in Ref. (65)] and autophagy-
independent pathways [reviewed in Ref. (66)]. Meanwhile, the 
observation that endogenously expressed TSHR A subunits are 
in general more efficient than non-cleaving TSHR and wild-
type TSHR for inducing TSAb and Graves’ hyperthyroidism in 
animal models (45) depicts another possible scenario, in which 
the shed TSHR A subunit might be internalized by MHC class 
II-positive thyrocytes and presented through the conventional 
lysosome/endosome-MHC class II pathway. It is possible that 
the pathways by which MHC molecules acquire peptides have 
a significant impact on the generation of peptide diversity that 
will be ultimately recognized by the T cells and give rise to 
diverse antibodies.
APC ADAPTATiON iN THYROCYTeS 
STiMULATeD BY CYTOSOLiC DNA
Major histocompatibility complex class II expression on the 
transferred fibroblasts was a key factor for the generation of TSAb 
in “Shimojo’s model” (24). In genetic immunization models, 
vaccines usually consist of TSHR-expressing vectors (plasmids 
or adenovirus) and sometimes with additional cytokine (such 
as IL-2, IL-4, and IL-12)-expressing vectors as adjuvants (36). 
However, none of these vaccines has ever included vectors that 
express MHC class II. At first glance, MHC class II expression 
would appear to be irrelevant in the genetic vaccine-induced 
Graves’ animals. Yet in 1999, Suzuki et al. surprisingly found that 
both MHC class I and II expression was strongly induced on the 
cell surface of cloned rat thyroid FRTL-5 cells after the cells were 
transfected with irrelevant or even empty plasmids. In order to 
dissect the cause for this aberrant MHC expression, they tried 
different transfection methods and reagents [e.g., lipofection, 
electroporation, and diethylaminoethyl (DEAE)-dextran] to 
introduce various DNA substances into FRTL-5 cells. They found 
that, regardless of the transfection methods and DNA origin, 
diverse DNA, including bacterial DNA, viral DNA, salmon sperm 
DNA, calf thymus DNA, self-genomic DNA, plasmid DNA, and 
artificially synthesized DNA (>25 bp), could induce significant 
MHC expression on FRTL-5 cells, whereas single-stranded DNA 
(ssDNA) could not (67). Later studies revealed that a classic 
double-stranded right-handed helix sense (B-DNA) with a native 
sugar–phosphate backbone is necessary for the aberrant MHC 
expression induced by DNA, and the effect was independent 
of sequence or presence of unmethylated CpG motifs (67–69). 
Moreover, free DNA in the extracellular medium did not induce 
MHC expression, indicating that this effect was likely mediated 
by cytosolic DNA sensors rather than cell surface receptors (67).
Besides MHC molecules, cytosolic DNA induces the expres-
sion of an array of molecules in thyrocytes that are involved in 
antigen-processing and -presenting pathways, such as protea-
some protein LMP2, transporter associated with antigen process-
ing (TAP), MHC II-associated invariant chain (Ii), costimulatory 
molecules (CD80, CD40, CD54, and CD86) (67, 70), and the 
production of various immune mediators, including type I IFN, 
TNF-α, and IL-6 (70). These observations indicate that thyrocytes 
were adapted to behave like APCs with activated innate immune 
response upon exposure to cytosolic DNA, a phenomenon that 
FiGURe 2 | A model for TSAb generation triggered by cell damage-derived self-genomic DNA. Self-genomic DNA released from damaged thyrocytes (left) 
enters neighboring cells (middle) and induces aberrant expression of MHC class II as well as costimulatory molecules needed for the MHC class II antigen 
presentation pathway in thyrocytes. At the same time, cytosolic DNA stimulates thyrocytes to produce various proinflammatory cytokines and chemokines that can 
recruit and activate helper T cells. CD4+ T cells that bind to MHC class II-antigen molecule cause B cell activation. The activated B cells then differentiate into plasma 
cells that may produce functional TRAbs to stimulate TSHR on the thyrocytes (right).
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has been widely reproduced in various non-professional APC 
cells (such as fibroblasts, keratinocytes, epithelial cells, and 
endothelial cells). Cytosolic DNA similarly enhances APC activ-
ity in professional APCs (67–71). Consistent with this finding, 
T cells were indeed activated to a higher degree, as measured 
by IL-2 and IFN-γ secretion levels, when they were mixed with 
peptide-challenged dendritic cells containing cytosolic DNA, 
compared to those without cytosolic DNA, or those containing 
ssDNA (71). Based on these findings, it is reasonable to speculate 
that muscle cells at the injection sites would express MHC class II 
and undergo adaptations to obtain some APC-like features after 
immunization with either plasmids or adenovirus (both contain 
dsDNA structures). These APC-like adaptations occurring in 
DNA-stimulated cells might have played a significant role to 
precipitate TSAb generation in animals and may also hold a key 
to understand the trigger for Graves’ disease in the humans.
CeLL iNJURY iNDUCeS APC ADAPTATiON 
VIA CYTOSOLiC DNA SiGNALS
Thyrocytes would likely encounter DNA in the cytosol following 
bacteria or virus infection that would introduce foreign DNA 
(72). Although abundant indirect data suggest the involvement of 
infecting organisms in the pathogenesis of AITD (72), there is no 
direct evidence for this possibility and thus the role of infection 
in AITD remains a subject of debate (73). In addition to foreign 
DNA, self-DNA that is normally sequestered within the nucleus 
or in the mitochondria can also enter the cytosol of phagocytes 
from apoptotic bodies released by dying cells in vivo. Phagocytes 
engulfing these apoptotic bodies from the extracellular medium 
would eliminate unnecessary DNA through DNase present in the 
phagolysosomes (74). DNase deficiency leads to the accumula-
tion of large amounts of cytosolic DNA in phagocytes derived 
from apoptotic cells (75). The ability to remove DNA waste is 
indispensable for in  vivo homeostasis. Defective clearance 
of self-DNA due to mutations in DNase genes is known to be 
associated with the development of human autoimmune diseases 
such as systemic lupus erythematosus (SLE) (76, 77), indicating 
that excessive self-DNA can be a potential trigger for breaking 
self-tolerance.
Even with normal DNase function, severe cellular injuries, 
depending on the magnitude, can result in a large amount 
of DNA waste that outpaces the intrinsic clearance rate of the 
phagocytes and, thus, would inevitably lead to rapid cytosolic 
DNA accumulation. In order to demonstrate whether sterile 
cell injury would cause cytosolic DNA accumulation that is suf-
ficient to induce an APC-like adaptation and stimulate an innate 
immune response in normal thyrocytes, Kawashima et al. applied 
electric pulses of increasing intensity to cultured thyrocytes and 
found that the amount of cytosolic DNA increased in a current 
intensity-dependent manner and correlated with significantly 
increased expression of a panel of DNA-inducible molecules, 
including MHC class II, class II transactivator (CIITA), CD40, 
CD80, CD86, IFN-β, TNF-α, IL-6, and CCL2 (67, 70). These 
results support the hypothesis that sterile cell injury can induce 
aberrant expression of MHC class II and costimulatory molecules 
and stimulate an innate immune response in the thyrocytes. On 
the other hand, transfected cytosolic dsDNA, but not ssDNA, 
suppressed iodide uptake and thyroid-specific functional gene 
sodium/iodide symporter (Slc5a5) expression in the thyrocytes 
(70). This result is in agreement with previous observations that 
thyroid function was suppressed when immune activation was 
7Luo et al. Cytosolic DNA Triggers Graves’ Disease
Frontiers in Endocrinology | www.frontiersin.org November 2016 | Volume 7 | Article 144
induced in the thyroid (78). Furthermore, mass spectrometry 
analysis identified histone H2B as a thyrocyte cytosol protein 
that bound to a dsDNA Sepharose column (70). Knockdown 
of histone H2B by siRNA abolished cell injury-induced innate 
immune activation and increased sodium/iodide symporter 
(NIS) expression (70), indicating that histone H2B may serve as a 
cytosolic DNA sensor that mediates the immune-activating effect 
of DNA in the cytosol.
Based on these studies, a novel model in which cell injury trig-
gers thyroid autoimmune reactions via cytosolic DNA signals in 
the thyrocytes has been proposed (79). In this model (Figure 2), 
fragments of self-genomic DNA released from damaged cells 
may enter neighboring cells to induce expression of essential 
molecules in the MHC class II antigen presentation pathway, and 
the production of type I IFN, proinflammatory cytokines, and 
chemokines that can recruit and activate lymphocytes and thy-
rocytes. Endogenous cytosolic TSHR or internalized shed TSHR 
A subunit may be presented by aberrantly expressed MHC class 
II on the thyrocytes, with the help of costimulatory molecules to 
fully activate CD4+ cells. CD4+ T cells that bind to MHC class 
II-antigen molecules cause activation of B cells, which then dif-
ferentiate into plasma cells that may produce functional TRAbs 
to stimulate TSHR. Thus, the cooperation of innate immune 
activation, inflammation, and aberrant expression of MHC class 
II and costimulatory molecules will consequently precipitate 
the generation of TSAbs under an autoimmune-prone genetic 
background (79).
CONCLUSiON
A number of successful mouse/hamster models of Graves’ disease 
have been established during the past two decades. Although 
each model has some limitations, together they have provided 
invaluable insight for understanding human Graves’ disease. To 
summarize findings from these models: (1) similar immuniza-
tion approaches yielded different outcomes in different mouse 
strains, indicating that genetic background plays an essential role 
in the development of TSAb; (2) free TSHR A subunits show sig-
nificant advantages over full-length TSHR for inducing TSAbs, 
suggesting that the epitopes recognized for the generation of 
functional TRAbs are likely exposed in the free TSHR A subunit; 
and (3) Shimojo’s model has particularly emphasized that aber-
rant expression of MHC class II on non-APCs is a contributing 
factor to Graves’ disease. In other words, the involvement of 
the MHC class II antigen presentation pathway in non-APCs 
(thyrocytes) may be an important step that leads to breaking of 
self-tolerance (36, 38, 80).
However, all existing animal models, strictly speaking, are 
not authentic Graves’ models as these animals were artificially 
immunized with antigens to induce antibody responses. The 
desired models that reflect the actual pathogenesis of Graves’ 
disease would have spontaneous disease onset without any arti-
ficial immunization of the causative antigen, i.e., TSHR, solely 
by modulating other factors that are suspected to trigger and/or 
accelerate autoimmune reactions. Such modulations may include 
the use of thyroid MHC class II/HLA-DR3 or CIITA transgenic 
mice, transfer of IFN-γ-pretreated syngeneic thyrocytes, increas-
ing intramolecular cleavage and shedding rate of in vivo TSHR on 
the thyrocytes, biasing the immune balance of the extracellular 
milieu by cytokine/chemokine administration, raising animals 
with special diets or housing environment, or these conditions in 
combination. If such a spontaneous model was to be successfully 
established, even with very low disease incidence will be the true 
model for understanding Graves’ disease pathogenesis and even 
to prevent and cure Graves’ disease.
Inspired by the discovery that cytosolic DNA structures can 
induce aberrant MHC class II expression on various non-APCs, 
including thyrocytes, and stimulate the production of various 
immune mediators, a DNA effect may pave the way for the success 
of genetic vaccination approaches. The demonstration that sterile 
cell injury results in cytosolic DNA accumulation correlated with 
aberrant expression of MHC class II and costimulatory molecules, 
as well as inflammatory cytokines and chemokines in thyrocytes, 
raised the possibility that cell injury may affect self-tolerance via 
cytosolic DNA signals. From this perspective, cellular DNA is not 
just a genetic code but also serves to alert adjacent healthy cells to 
danger by interacting with a series of cellular sensors. Moreover, 
if the amount of cytosolic DNA that is derived from severe tissue 
damage and/or its deficient clearance exceeds a certain threshold, 
maintenance of self-tolerance may be at risk. The discovery that 
cell injury-derived excess self-DNA is a potential trigger for initi-
ating thyroid autoimmune reactions may also help to generate an 
authentic Graves’ animal model in the future.
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